Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Autonomous & Electric Vehicles (DRIV) vs BIO-TECHNE Corp (TECH) Price & Performance

Global X Autonomous & Electric VehiclesTrade
BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

Global X Autonomous & Electric Vehicles vs BIO-TECHNE Corp — how do they compare? Global X Autonomous & Electric Vehicles trades at $35.42, while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp pays a 0.44% dividend while Global X Autonomous & Electric Vehicles pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Global X Autonomous & Electric Vehicles nearer its low. Which is the better fit depends on your goals.

DRIVTECH
Sector
Sector/ThematicHealth
52-Week High
$42.53$72.29
52-Week Low
$25.21$43.31
Market Cap
$11.24B
Enterprise Value
$11.32B
Dividend Yield
0.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Autonomous & Electric Vehicles

DRIV trades at $35.78, up 2.55% today, with a bullish technical signal driven by moving averages. The stock shows strong year-to-date performance, supported by positive sentiment in the electric vehicle sector. Key support is at $35, with resistance at $36. Recent news highlights global EV sales growth and China's expanding market ambitions.

Outlook remains positive due to sector tailwinds and autonomous driving advancements, but risks include regulatory pressures and competitive threats from Chinese automakers. Institutional interest is strong, though overbought RSI signals caution near-term.

BIO-TECHNE Corp

Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.

Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.

Returns comparison

Trailing returns across standard periods

About Global X Autonomous & Electric Vehicles

DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.

Read more on DRIV

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH